Analysis Presented at WCLC Highlights Variance Between Oncologists and Expert Recommendations in Intended Immunotherapy Treatment for Advanced NSCLC
Clinical Care Options' data presented at the 19th World Conference on Lung Cancer suggest oncologists' planned treatment approach for advanced NSCLC patients often differs from expert recommendations
RESTON, Va., Nov. 19, 2018 /PRNewswire-PRWeb/ -- Oncologists often select different treatment approaches compared with expert recommendations, according to an analysis of data captured with an online decision support tool developed by Clinical Care Options (CCO) in collaboration with 5 lung cancer experts. Detailed analysis of the data was presented by David R. Gandara, MD, at the 19th World Conference on Lung Cancer in Toronto, Ontario.
The treatment for advanced non-small-cell lung cancer (NSCLC) is in the midst of a striking revolution with the advent and expansion of immune checkpoint inhibitors into the current treatment paradigm. This makes it challenging for many oncologists to make informed treatment decisions for their patients.
CCO collaborated with 5 NSCLC experts—David R. Gandara, MD; Melissa L. Johnson, MD; Suresh S. Ramalingam, MD; Heather Wakelee, MD; and H. Jack West, MD—to update an online tool that provides patient- and disease-specific guidance on treatment decisions for advanced NSCLC. The impact of the tool in this rapidly changing clinical area was evident in the setting of high PD-L1 expression for newly diagnosed patients where 66% of participants indicated that the recommendations provided by the tool changed their management plan.
"The data regarding the planned implementation of immunotherapy from this tool are very interesting, especially the differences between expert recommendations and the oncologists using the tool, as well as the treatment trends of both the expert recommendations and oncologists over time," said David R. Gandara, MD, Director, Thoracic Oncology Program, Professor of Medicine, and Senior Advisor to Director, UC David Comprehensive Cancer Center. "In addition, we found that expert recommendations often changed the intended treatment plan of oncologists, consistent with the potential of this online tool to improve clinical outcomes in patients with advanced NSCLC."
The goal going forward is to continue to update this online tool as the treatment of patients with advanced NSCLC rapidly evolves to provide a useful resource for healthcare providers and patients. An update is currently in progress to capture the recent changes in NSCLC treatment. The most recent version of this tool can be found at http://www.clinicaloptions.com/LungTool
Gandara DR, Quill TA, Edelman MJ, Ramalingam SS, Wakelee HA, West HJ, Obholz KL. Evolving Immunotherapy Practice Patterns in Advanced NSCLC: Analysis of an Online Treatment Decision Tool. Program and abstracts of the IASLC 19th World Conference on Lung Cancer; September 23-26, 2018; Toronto, Canada.
About Clinical Care Options
Clinical Care Options, LLC, is a global leader in the development of innovative educational programs and technology platforms. CCO's team has been a pioneer in the creation of continuing education and decision support resources for healthcare professionals both in the United States and around the world for more than 2 decades. For more information, visit clinicaloptions.com.
Contact:
Tradd Sanderson | Director of Marketing
Clinical Care Options
Telephone: 855.224.2241
Email: [email protected]
SOURCE Clinical Care Options
Share this article